Clinical trial
A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
NCT01203943 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Sequential, Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetic and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- Celgene
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 1, 2011
- Completion date
- August 24, 2012
- Enrollment
- 28 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.
fibrosis, idiopathic pulmonary fibrosis, interstitial lung disease, lung diseases, interstitial, pulmonary fibrosis